Holden Leads Blog
Data, outreach strategies, and market intelligence for cannabis B2B professionals.
Glass House hit the NYSE, Vireo paid $20M to enter Pennsylvania, and the Teamsters struck a grow. The week in cannabis deals and what it signals for B2B.
Read more →Pre-rolls overtook flower as cannabis's top category by units in 2026, led by infused pre-rolls. Here's the data and what the shelf shift means for B2B sellers.
Read more →Q1 2026 cannabis earnings split the big operators: Green Thumb grew revenue, Trulieve shrank but printed cash. Here's what it means for who can buy.
Read more →CBN, CBG, and THCV are 2026's anticipated breakout, with shoppers buying by blend over strain name. Here's what it means for dispensary shelves.
Read more →Most cannabis B2B outreach dies at the front desk. Here's how to reach the dispensary owner who can actually say yes, and why your channel matters.
Read more →DEA marijuana rescheduling hearing starts June 29, 2026. See what Schedule III already changed for licensed dispensaries, and what's still in play.
Read more →It was a humbling week for anyone who likes their cannabis science tidy. A major international study suggested that how a country legalizes matters more than whether it does.
Read more →Walk into a dispensary this June and you can see two cannabis industries sharing the same shelf. On one side sit the trophy strains: small-batch, terpene-loud, genetics-obsessed flower that connoisseurs hunt by name.
Read more →Cannabis policy in the United States is being shaped this summer not by a single dramatic vote but by two ticking clocks, and this week pushed both closer to zero.
Read more →If you wanted a single snapshot of where the cannabis business stands in mid-2026, you could not have asked for a clearer one than the run of financial filings that landed this week.
Read more →